Dogwood Therapeutics (DWTX) Cash & Equivalents (2020 - 2026)

Dogwood Therapeutics (DWTX) has reported Cash & Equivalents for 7 consecutive years, with $13.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 24.58% year-over-year to $13.2 million; the TTM figure through Mar 2026 stood at $13.2 million (down 24.58% YoY), while the FY2025 annual figure was $6.5 million, down 56.06% from the prior year.
• Cash & Equivalents improved to $13.2 million in Q1 2026 per DWTX's latest filing, from $6.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $17.5 million in Q1 2025 and bottomed at $2.0 million in Q3 2024.
• Historically, Cash & Equivalents has averaged $8.1 million across 5 years, with a median of $7.0 million in 2022.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 64.76% — and 2025, when it jumped 637.08%.
• Dogwood Therapeutics' Cash & Equivalents stood at $7.0 million in 2022, then tumbled by 52.82% to $3.3 million in 2023, then surged by 347.64% to $14.8 million in 2024, then plunged by 56.06% to $6.5 million in 2025, then jumped by 102.73% to $13.2 million in 2026.
• Business Quant data shows DWTX's Cash & Equivalents at $13.2 million in Q1 2026, $6.5 million in Q4 2025, and $10.1 million in Q3 2025.